Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CDW
Sha Tin, New Territories, Hong Kong
- Ownership
- Private
- Development stage
- Other
01
Overview
CDW (through subsidiary ABio) is engaged in joint R&D on next-generation lipid nanoparticle delivery technologies for mRNA, antibody, and nucleic acid therapeutics; clinical results have not yet been announced, work is preclinical.
- Modalities
- AntibodyRecombinant proteinLipid nanoparticle delivery therapymRNA-based drugs
- Industry
- Biotech
02
Partnerships
Neoregen Biotech Co., Ltd.Premier (for CDW Healthcare US IT services, not biotech)
Beyond the preview
Go deeper on CDW.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDW.